MetLife Investment Management LLC Has $30,000 Stock Position in Caribou Biosciences, Inc. (NASDAQ:CRBU)

MetLife Investment Management LLC decreased its stake in Caribou Biosciences, Inc. (NASDAQ:CRBU) by 68.7% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 15,256 shares of the company’s stock after selling 33,503 shares during the quarter. MetLife Investment Management LLC’s holdings in Caribou Biosciences were worth $30,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Renaissance Technologies LLC purchased a new stake in Caribou Biosciences in the 2nd quarter worth about $2,432,000. Dimensional Fund Advisors LP lifted its stake in Caribou Biosciences by 25.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,623,283 shares of the company’s stock worth $4,302,000 after acquiring an additional 536,162 shares in the last quarter. XTX Topco Ltd purchased a new stake in Caribou Biosciences in the 2nd quarter worth about $341,000. Milestone Asset Management LLC purchased a new stake in Caribou Biosciences in the 2nd quarter worth about $233,000. Finally, Charles Schwab Investment Management Inc. lifted its stake in Caribou Biosciences by 19.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 739,530 shares of the company’s stock worth $1,449,000 after acquiring an additional 118,325 shares in the last quarter. Institutional investors and hedge funds own 77.51% of the company’s stock.

Caribou Biosciences Price Performance

CRBU opened at $2.03 on Wednesday. The business has a 50-day moving average of $2.08 and a 200-day moving average of $2.06. Caribou Biosciences, Inc. has a fifty-two week low of $1.50 and a fifty-two week high of $8.33. The company has a market capitalization of $183.82 million, a PE ratio of -1.23 and a beta of 2.27.

Caribou Biosciences (NASDAQ:CRBU) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.06. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. The business had revenue of $2.02 million for the quarter, compared to the consensus estimate of $3.37 million. On average, equities research analysts expect that Caribou Biosciences, Inc. will post -1.64 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on CRBU. Citigroup reduced their price objective on Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, November 26th. HC Wainwright reaffirmed a “buy” rating and set a $9.00 price target on shares of Caribou Biosciences in a research note on Friday, November 15th. Four research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $10.20.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.